Regeneron Pharmaceuticals (REGN) Profit After Tax (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Profit After Tax of $1.3 billion for Q2 2026, down 8.35% year-over-year from $1.4 billion in Q2 2025, and up 78.34% quarter-over-quarter from $727.2 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Profit After Tax (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Profit After Tax history runs 18 years deep, the most recent figure standing at $1.3 billion for Q2 2026.
- In Q2 2026, Profit After Tax fell 8.35% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $4.4 billion (down 4.19% YoY), while the FY2025 annual figure was $4.6 billion, up 2.33% from the prior year.
- Profit After Tax for Q2 2026 stood at $1.3 billion, up from $727.2 million in the prior quarter.
- The five-year high for Profit After Tax was $1.5 billion in Q3 2025, with the low at $722.0 million in Q1 2024.
- The 5-year median for Profit After Tax is $1.0 billion (2022), against an average of $1.1 billion.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax sank 72.5% in 2022, then surged 47.9% in 2024.
- Regeneron Pharmaceuticals' Profit After Tax stood at $1.2 billion in 2022, then grew by 4.88% to $1.3 billion in 2023, then sank by 32.33% to $849.6 million in 2024, then gained by 0.41% to $853.1 million in 2025, then surged by 52.02% to $1.3 billion in 2026.
- Business Quant data shows REGN's Profit After Tax at $1.3 billion in Q2 2026, $727.2 million in Q1 2026, and $853.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | -65.60 Mn |
| Dec 31, 2025 | -3.65 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Mar 31, 2025 | 845.70 Mn |
| Dec 31, 2024 | -3.42 Bn |
| Sep 30, 2024 | 1.34 Bn |
| Jun 30, 2024 | 7.30 Mn |
| Mar 31, 2024 | 722.00 Mn |
| Dec 31, 2023 | 1.16 Bn |
| Sep 30, 2023 | 1.03 Bn |
| Jun 30, 2023 | 968.40 Mn |
| Mar 31, 2023 | 817.80 Mn |
| Dec 31, 2022 | 1.20 Bn |
| Sep 30, 2022 | 1.26 Bn |
| Jun 30, 2022 | 852.10 Mn |
| Mar 31, 2022 | 973.50 Mn |
| Dec 31, 2021 | 2.25 Bn |
| Sep 30, 2021 | 1.63 Bn |